0.88
+0.0129(+1.49%)
Currency In USD
| Previous Close | 0.87 |
| Open | 0.88 |
| Day High | 0.88 |
| Day Low | 0.87 |
| 52-Week High | 1.6 |
| 52-Week Low | 0.65 |
| Volume | 53,687 |
| Average Volume | 853,135 |
| Market Cap | 53.65M |
| PE | -0.82 |
| EPS | -1.07 |
| Moving Average 50 Days | 0.79 |
| Moving Average 200 Days | 0.9 |
| Change | 0.01 |
If you invested $1000 in Kronos Bio, Inc. (KRON) since IPO date, it would be worth $32.51 as of July 06, 2025 at a share price of $0.88. Whereas If you bought $1000 worth of Kronos Bio, Inc. (KRON) shares 3 years ago, it would be worth $212.05 as of July 06, 2025 at a share price of $0.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
May 01, 2025 12:30 PM GMT
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcriptio
Kronos Bio Announces CEO Transition and Reduction in Force
GlobeNewswire Inc.
Nov 27, 2024 12:30 PM GMT
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
GlobeNewswire Inc.
Nov 14, 2024 9:02 PM GMT
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. an
Data not available